According to reports from Essential Business Intelligence, Lord's Mark Industries Limited has announced ambitious financial targets for FY2027, expecting consolidated revenue of at least ₹1,550 crore, representing over 20% growth compared to FY2026. The company anticipates Profit After Tax (PAT) of at least ₹178 crore at a margin of 11.4%, reflecting a margin expansion of over 200 basis points. The majority of FY2027 growth will be driven by core operations in in-vitro diagnostics and renewable energy, with further operational momentum expected from FY2028 onward through the commercialization of its sickle cell testing business and medical device platforms including Onco Spectra and TB Truth. Managing Director Sachidanand Upadhyay stated that the guidance reflects the strength of existing operations, with top-line growth of at least 20% and PAT growth of at least 50%. Speaking on the developments, Upadhyay emphasized that Lord's Mark stands at the most important inflection point in its history, noting that healthcare in India is moving from scarcity to access, and the company intends to be one of the companies that makes that transformation happen.
As reported by Essential Business Intelligence, the Board of Directors has proposed to demerge its Renewable Energy and LED business into a separate entity, Lords Shakti Power Limited, by March 2027. Lord's Mark Industries will hold 60% in the resulting company, with existing shareholders receiving mirror equity. The demerged energy business will also expand into power transmission through transformer manufacturing, allowing the company to optimize capital allocation and enable standalone healthcare evaluation. This strategic move represents a transformative expansion of the company's global healthcare platform alongside the proposed corporate restructuring.
According to the company announcement, Lord's Mark Industries is entering an exclusive agreement with a leading global manufacturer to bring CAR-T cell therapy to India across five specialized centers, starting with Mumbai and Bangalore by March 2027. The company is significantly lowering treatment costs to widen patient access through this partnership. Through its new subsidiary, Lords Mark Medicure Limited, the company is launching an oncology hospital network in tier-2 cities to address critical care shortages, beginning with two pilot 70-bed hospitals in Vapi and Solapur supported by a planned ₹200 crore debt raise in December 2026. Additionally, the company plans to establish 50 company-operated dialysis centers across India by March 2027 equipped with its proprietary RENALOS machines to transition toward recurring service revenues.
As reported by Essential Business Intelligence, the company has incorporated Lords Mark Industries UK Limited—the first Indian company registered under the India-UK Free Trade Agreement—and is establishing Lords Mark Industries Swiss Limited. Both entities will operate captive pathology laboratories supplied entirely from Indian manufacturing facilities while distributing diagnostic supplies across European markets, with an application for NHS approval submitted. The subsidiary opens a developed-market channel for the company's IVD manufacturing base at international price points, expanding its global footprint significantly.
According to the company announcement, on the innovation front, patient trials have been completed for the OneDNA genomic testing platform following ICMR approval. The Biomescan Analytics Platform became the first software-as-a-medical-device (SaMD) in India to receive a manufacturing license under the Medical Devices Rules, 2017. Managing Director Sachidanand Upadhyay emphasized that the guidance reflects the strength of existing operations, with the company standing at the most important inflection point in its history. He noted that healthcare in India is moving from scarcity to access, and Lord's Mark intends to be one of the companies that makes that transformation happen.
